Pharmacology ACS Pharmacology & Translational Science
Review: Adding Exercise to Incretin Drugs Remains Unproven in Obesity
- A systematic review of 31 studies pooled roughly 10,000 adults with excess weight and compared incretin drugs, exercise, and the two together.
- Drugs reliably beat placebo or usual care on weight and glycaemia, but few trials tested drug plus exercise head-to-head against drug alone.
- Exercise regimens varied widely, often amounting to counselling, so any complementary benefit for fitness or weight maintenance is only tentative.
Thirty-one studies and almost no head-to-head drug+exercise versus drug-alone arms: the question clinicians actually ask is barely tested. The pharmacologically interesting endpoint is lean-mass preservation during incretin weight loss, which needs DXA or MRI body composition, not scale weight. Until trials use standardized, supervised training with body-composition and fitness readouts, 'add exercise' stays a plausible hypothesis, not evidence.
Paper: ACS Pharmacology & Translational Science ↗ Incretin Receptor Agonists and Exercise in Obesity, a Systematic Review with Exploratory Meta-analysis of Comparative and Combined Evidence